Clinical trial
Study of Thymosin Beta 4 in Patients With Pressure Ulcers
NCT00382174 · RegeneRx Biopharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00382174 |
|---|---|
| Title | Study of Thymosin Beta 4 in Patients With Pressure Ulcers |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Pressure Ulcers |
| Lead sponsor | RegeneRx Biopharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pressure Ulcers |
| Intervention type | Drug |
| Interventions | Placebo, Thymosin Beta 4 |
| Enrollment | 72 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 28, 2006 |
| Last update posted | Feb 1, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: